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G E N E T I C S
Evolutionarily conserved regulation of sleep by 
epidermal growth factor receptor signaling
Daniel A. Lee1, Justin Liu1, Young Hong1, Jacqueline M. Lane2,3, Andrew J. Hill1,  
Sarah L. Hou1, Heming Wang2,3, Grigorios Oikonomou1, Uyen Pham1, Jae Engle1, 
Richa Saxena2,3,4, David A. Prober1*
The genetic bases for most human sleep disorders and for variation in human sleep quantity and quality are largely 
unknown. Using the zebrafish, a diurnal vertebrate, to investigate the genetic regulation of sleep, we found that 
epidermal growth factor receptor (EGFR) signaling is necessary and sufficient for normal sleep levels and is re-
quired for the normal homeostatic response to sleep deprivation. We observed that EGFR signaling promotes 
sleep via mitogen-activated protein kinase/extracellular signal–regulated kinase and RFamide neuropeptide sig-
naling and that it regulates RFamide neuropeptide expression and neuronal activity. Consistent with these findings, 
analysis of a large cohort of human genetic data from participants of European ancestry revealed that common 
variants in genes within the EGFR signaling pathway are associated with variation in human sleep quantity and 
quality. These results indicate that EGFR signaling and its downstream pathways play a central and ancient role in 
regulating sleep and provide new therapeutic targets for sleep disorders.
INTRODUCTION
Identifying how sleep is regulated is a critical health priority. Sleep 
loss and sleep disorders are among the most common, yet frequently 
overlooked, human health problems. An estimated 50 to 70 million 
Americans suffer from a chronic sleep disorder (1), but the genetic 
and neural mechanisms that regulate human sleep remain poorly 
understood. Large-scale human genome-wide association studies 
(GWAS) have recently identified genomic regions associated with 
variation in human sleep and several sleep disorders (2–8), but in 
most cases, the causative gene(s) remains unclear, and most genes 
identified in these studies have not been validated in vivo. With the 
exception of narcolepsy, which results from loss of hypocretin 
(Hcrt) neurons (1), and circadian disorders that affect sleep timing 
(1), the genetic basis for variation in human sleep and sleep disorders 
is largely unknown.
Sleep is an evolutionarily conserved behavioral state defined as a 
period of rapidly reversible immobility and increased arousal 
threshold that is under homeostatic control, such that prolonged 
wakefulness leads to a compensatory increase in sleep duration and 
intensity (9). This definition is valid for complex organisms such as 
humans, for simpler vertebrate animal models such as rodents and 
zebrafish, and for invertebrates such as Caenorhabditis elegans and 
Drosophila melanogaster (9, 10). However, while recent studies have 
begun to reveal mechanisms that regulate sleep in either invertebrate 
or vertebrate model organisms, there is relatively little evidence for 
conserved genetic or neuronal mechanisms that regulate sleep in both 
vertebrates and invertebrates. While neuronal circuits that regulate 
sleep in Drosophila and C. elegans have been described in detail (11), 
there are no clear vertebrate homologs for these invertebrate neuro-
nal systems. Similarly, the few signaling pathways implicated in reg-
ulating vertebrate sleep, such as Hcrt- and melanin-concentrating 
hormone signaling, lack unambiguous invertebrate orthologs (10). 
As a result, it is unclear whether mechanisms that regulate sleep 
evolved independently in invertebrate and vertebrate species and 
whether mechanisms identified in invertebrates are relevant to sleep 
in humans. Identifying conserved mechanisms, if they exist, would 
be valuable because they would likely have central roles in regulating 
sleep and may provide novel therapeutic targets for sleep disorders.
Among the peptidergic signaling pathways known to regulate 
invertebrate sleep, the pathway with perhaps the clearest homology 
in vertebrates is that of the epidermal growth factor (EGF) receptor 
(EGFR) and its ligands. EGFR signaling has primarily been studied 
for its roles in development and physiology, but more recently it 
has also been implicated in regulating several behaviors (12–20). 
Genetic gain- and loss-of-function studies in Drosophila and C. elegans 
have demonstrated that EGFR signaling is both necessary and 
sufficient for normal sleep levels in these invertebrate animals 
(12, 13, 16, 19, 21, 22). Furthermore, a GWAS using a panel of inbred 
wild-caught Drosophila lines identified an association between com-
mon variants in several EGFR pathway genes and sleep duration (17), 
as did an artificial selection screen for long and short sleep duration in 
an outbred Drosophila population (18). These GWAS observations 
suggest that EGFR signaling plays a role in natural sleep varia-
tion in Drosophila. However, mechanisms that link EGFR signaling 
to downstream sleep regulators are poorly understood. It is also un-
clear whether EGFR signaling regulates sleep in vertebrate model 
organisms and in humans.
Here, we address the role of EGFR signaling and downstream 
mechanisms in regulating sleep using the zebrafish, a vertebrate 
with established, behaviorally defined diurnal sleep (23). This model 
organism has several advantages over more commonly used rodent 
species for modeling aspects of human sleep, including a simpler, 
yet anatomically and molecularly conserved, vertebrate brain; rapid 
development with complex behaviors such as sleep present in 
5-day-old animals; amenability to high-throughput behavioral assays; 
and amenability to genetic and pharmacological manipulations (10). 
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Furthermore, zebrafish sleep has genetic, pharmacological, and 
neuroanatomical similarities to mammalian sleep (10), suggesting 
that findings in zebrafish will translate to mammals.
Using genetics and pharmacology, we show that EGFR signaling 
is both necessary and sufficient for normal sleep duration, promotes 
consolidation and maintenance of sleep, and is required for the normal 
sleep rebound response to sleep deprivation (SD) in zebrafish. In 
addition, we show that EGFR signaling promotes sleep in zebrafish 
via mitogen-activated protein kinase (MAPK)/extracellular signal–
regulated kinase (ERK) and RFamide neuropeptide signaling, and 
describe a mechanism linking the EGFR and RFamide neuropeptide 
systems. Last, by analyzing a large cohort of human genetic data (24), 
we identify associations between sleep duration and quality measures 
with common variants in genes that participate in EGFR signaling. 
These results establish EGFR signaling as an evolutionarily conserved 
sleep-promoting system with implications for human sleep disorders.
RESULTS
Transforming growth factor, alpha overexpression  
increases sleep
To explore the role of EGFR signaling in vertebrate sleep, we first 
characterized the expression pattern of each zebrafish ortholog of 
EGFR and its ligands in the brain at 5 days postfertilization (dpf) 
using in situ hybridization (ISH). We found that one EGFR paralog, 
egfra, is expressed in juxtaventricular cells that colocalize with sox2 
(Fig. 1, A, A″, and B), a marker of glial and ependymal cells (25), as 
well as in the hypothalamus, hindbrain, tectum, and cerebellum (Fig. 1, 
A′ and A″). The EGFR ligands transforming growth factor, alpha (TGFa) 
and EGF are implicated in regulating mammalian behavior (14, 20, 26), 
and each gene has a single zebrafish ortholog. Zebrafish egf  is expressed 
just dorsal to eg f ra-expressing cells in the diencephalon (fig. S1A). 
Similar to mammals and zebrafish egf  (27), zebrafish tgfa is also ex-
pressed in juxtaventricular cells in the diencephalon, just dorsal to 
egfra-expressing cells (Fig. 1, C and C′), that also express sox2 
(Fig. 1, D and D′). We observed a significant day/night oscillation 
in tgfa mRNA level by reverse transcription quantitative polymerase 
chain reaction (qPCR) [P < 0.05, one-way analysis of variance 
(ANOVA)], with peak tgfa expression at 12 a.m. 150% higher than 
the trough at 12 p.m. in animals entrained under 14-hour light/10-hour 
dark conditions until 6 dpf (P < 0.05, one-way ANOVA, Holm-Sidak 
test; fig. S1, B and C), consistent with a potential role for tgfa in reg-
ulating sleep. On the basis of these results, we tested the roles of tgfa 
and egfra in zebrafish sleep.
To test whether EGFR signaling is sufficient to promote sleep, 
we used a genetic strategy to conditionally overexpress TGFa while 
monitoring behavior using a video tracking assay (28). As previously 
established using locomotor activity and arousal threshold assays, a 
period of 1min (or longer) of inactivity corresponds to a sleep bout 
in zebrafish larvae (28). We generated Tg(hs:tgfa) zebrafish, in 
which a heat shock (HS)–inducible promoter regulates expression 
of zebrafish tg fa. Before HS, we observed no difference in locomotor 
activity or sleep between transgenic animals and their wild-type (WT) 
siblings (Fig. 1, E to H). In contrast, after HS-induced TGFa over-
expression, transgenic animals were less active and slept more than 
their WT siblings during both the night and the following day (night 
activity, −53%; day activity, −52%; night sleep, +54%; day sleep, +400%; 
P < 0.005, two-way ANOVA, Holm-Sidak test) (Fig. 1, E to H). The 
increase in sleep was most pronounced during the day, when zebrafish 
are normally most awake. This phenotype was due to an increase in 
sleep bout length during both the night and day, an increase in the 
number of sleep bouts during the day, and a decrease in wake bout 
length during the day (fig. S1, D to F). TGFa-overexpressing animals 
also exhibited a decrease in sleep latency (time to first sleep bout 
following lights on or off) during the day and a decrease in daytime 
and nighttime waking activity (locomotor activity while awake) (fig. S1, 
G and H). Thus, activation of EGFR signaling results in increased 
sleep due to consolidation of the sleep state and decreased sleep latency.
Genetic loss of EGFR signaling decreases sleep
We next tested the hypothesis that EGFR signaling is required for 
normal sleep levels by creating zebrafish with mutations in eg fra and 
its ligands. Mice containing a null mutation in Tgfa are viable and 
fertile (29), but sleep studies using this mutant have not been reported. 
Using the transcription activator–like effector nuclease (TALEN) 
method (30), we generated a zebrafish tgfa  mutant that is predicted 
to lack all known functional domains and should thus be a null muta-
tion (fig. S2A). tgfa−/− zebrafish are viable and fertile, with no apparent 
morphological abnormalities. Consistent with the TGFa overexpres-
sion phenotype, tgfa−/− animals were 15% more active and slept 28% 
less than their tgfa+/+ siblings during the day (activity, P < 0.005; 
sleep, P < 0.01; one-way ANOVA, Holm-Sidak test; fig. S1, I to L). 
These effects were primarily due to fewer sleep bouts and higher levels 
of waking activity (fig. S1, M to Q).
To ask whether EGF also contributes to sleep regulation, we used 
CRISPR-Cas9 (31) to isolate an egf  mutant that is predicted to lack 
all known functional domains after the initial three EGF-like domains 
and should thus be a null mutation (fig. S2B). Similar to tgfa−/− animals, 
egf −/− animals were 26% more active and showed a trend of less sleep 
than their egf +/+ siblings during the day (activity, P < 0.01; sleep, 
P = 0.10; one-way ANOVA, Holm-Sidak test; fig. S1, R to U), with 
sleep architecture phenotypes more modest than those observed in 
tg fa mutants (fig. S1, V to Z). To ask whether egf  and tg fa act redun-
dantly, we compared the behavior of egf −/−; tgfa−/− animals to their 
egf +/−; tg fa−/− and egf +/+; tg fa−/− siblings. We found that tg fa−/−; 
egf−/− animals are viable and fertile, with no apparent morphological 
abnormalities. egf −/−; tg fa−/− animals were more active and slept less 
during the day (activity, +20%; sleep, −45%; P < 0.005, one-way 
ANOVA, Holm-Sidak test) and slept less at night (−13%; P < 0.05, 
one-way ANOVA, Holm-Sidak test) compared to their egf +/+; tg fa−/− 
siblings (Fig. 2, A to D). The decrease in sleep was due to fewer sleep 
bouts and longer wake bouts during the day and shorter sleep bouts 
at night (fig. S1, AA to AE), suggesting that loss of both egf  and tgfa 
results in consolidation of wakefulness during the day and sleep frag-
mentation at night. These results suggest that tg fa and egf  have par-
tially redundant roles in EGFR-mediated sleep since loss of both 
genes resulted in a stronger sleep defect (day sleep, −45%; P < 0.005; 
night sleep, −13%; P < 0.05; one-way ANOVA, Holm-Sidak 
test; Fig. 2, C and D) than loss of tg fa alone (day sleep, −28%; 
P < 0.01; night sleep, −4.7%, P > 0.05; one-way ANOVA, Holm-Sidak 
test; fig. S1, I to Q).
We next tested whether EGFR is required for normal sleep levels 
in zebrafish. Egfr knockout mice are embryonic lethal, likely because 
of defects in placental development (32), thus preventing genetic 
loss-of-function sleep studies. However, since zebrafish develop 
ex utero without a placenta and contain at least two egfr paralogs (egfra 
and egfrb) (33), we reasoned that we could analyze the requirement 
for EGFR in zebrafish sleep. Since we found that egfra is expressed 
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in juxtaventricular cells adjacent to tg fa- and egf-expressing cells 
(Fig. 1, A′, A″, C, and C′, and fig. S1A), we used CRISPR-Cas9 to 
generate a zebrafish egfra mutant that is predicted to lack the trans-
membrane and intracellular domains (fig. S2C). egfra−/− animals 
are viable and lack obvious morphological abnormalities. Similar to 
EGFR ligand double mutants, egfra−/− animals were more active 
and showed a trend of less sleep during the day (activity, +17%; 
P < 0.005; sleep, −22%; P = 0.08; one-way ANOVA, Holm-Sidak 
test) and also slept less at night (−11%; P < 0.005, one-way ANOVA, 
Holm-Sidak test) compared to their egfra+/+ siblings (Fig. 2, E to H). 
Similar to EGFR ligand double mutants, the egfra mutant pheno-
type was primarily due to fewer sleep bouts during the day and 
shorter sleep bouts at night (fig. S1, AF to AJ), suggesting that loss 
of egfra results in sleep fragmentation at night. Together, these re-
sults suggest that tg fa, egf, and egfra are required for normal sleep 
levels in zebrafish. More broadly, the zebrafish genome contains 
several additional EGFR ligands, a second egfr paralog (33), and 
several ERBB family co-receptors that can form heterodimers with 
EGFR that can be activated by EGFR ligands; some of these proteins 
may also play roles in EGFR signaling–mediated sleep.
Pharmacological inhibition of EGFR signaling  
decreases sleep
To address the possibility that EGFR family members, in addition 
to egfra, promote sleep, we acutely and selectively inhibited the 
function of EGFRs by treating WT animals with the EGFR small- 
molecule inhibitors gefitinib and erlotinib (34). These compounds 
inhibit receptor function by binding to the adenosine triphosphate–
binding pocket of the tyrosine kinase domain (34), which has >90% 
amino acid similarity between humans and zebrafish (33). We found 
B B´ D
F
HG
E
A˝A´A C´C
D´
Fig. 1. TGFa overexpression increases sleep. (A to D) ISH of egfra and tgfa in the 5-dpf zebrafish brain (schematic) (A). A, anterior; L, lateral; V, ventral; Ce, cerebellum; 
Hy, hypothalamus; TeO, tectum. (A′ and A″) Sagittal (A′) and dorsal (A″) views of egfra expression in juxtaventricular cells (white arrowheads). (B and B′) egfra coexpression 
with sox2 in these cells. (C and C′) Sagittal (C) and dorsal (C′) views of tgfa expression in cells just dorsal to juxtaventricular cells in the diencephalon (white arrowheads). 
(D and D′) tgfa coexpression with sox2 in these cells (white arrowheads). Dashed lines in (A′) and (C) indicate the horizontal planes shown in (A″) and (C′). Boxed regions in 
(B) and (D) are magnified in (B′) and (D′). Dashed line in (D) shows outline of brain. Scale bars, 30 m (B, B′, D, and D′) and 50 m (A″ and C′). (E to H) Following a 1-hour HS 
(yellow bars), Tg(hs:tgfa) animals were less active (E and F) and slept more (G and H) than their WT siblings. Pre-HS and post-HS are calculated for the day or night before, 
and the day or night after, HS, respectively. White and black bars indicate day (14 hours) and night (10 hours). Data are obtained from two pooled experiments. Bar graphs 
show mean ± SEM. n = number of animals. m/h, minutes/hour; s/h, second/hour. ***P < 0.0001 by two-way ANOVA with Holm-Sidak test.
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that gefitinib-treated WT animals were more active (day, +23%; night, 
+30%) and slept less (day, −29%; night, −22%) than vehicle-treated 
siblings during both the day and night (P < 0.0001, Student’s t test; 
Fig. 2, I to L). This phenotype was due to fewer sleep bouts during 
the day, shorter sleep bouts at night, and longer wake bouts during 
the day and night (fig. S3, C to E), suggesting that inhibition of 
EGFR signaling results in fragmented sleep at night and consolidated 
wakefulness during the day and night. Gefitinib treatment also in-
creased waking activity and increased sleep latency during the day 
and night (fig. S3, F and G), suggesting that EGFR signaling is required 
for the normal initiation of sleep. Erlotinib treatment induced a similar 
behavioral phenotype (fig. S3, H to P). Gefitinib treatment did not 
further decrease sleep in egfra−/− animals (fig. S3, A and B), suggesting 
that pharmacological inhibitors of EGFR promote sleep largely by 
inhibiting egfra, that gefitinib-induced sleep is not due to nonspecific 
effects on other proteins, and that EGFR ligands promote sleep primarily 
via egfra. Together, these pharmacological and genetic results demon-
strate that EGFR signaling is required for normal sleep levels.
EGFR signaling modulates arousal threshold
Sleep is distinguished from quiet wakefulness by an increased arousal 
threshold, which we assayed by monitoring the behavioral response 
of zebrafish to a mechano-acoustic stimulus (35). We quantified the 
fraction of animals that responded to the stimulus at 14 different 
intensities and used these data to construct stimulus-response curves. 
We observed that the tapping intensity at which the half-maximal 
response occurred [effective tap power 50 (ETP50)] for TGFa- 
overexpressing larvae was 252% higher than that of their WT sib-
lings (F1,834 = 20.95, P < 0.0001 by extra sum-of-squares F test) 
(Fig. 3A). Conversely, the ETP50 for gefitinib-treated animals was 
37% lower than that of their vehicle-treated siblings (F1,834 = 18.16, 
P < 0.0001 by extra sum-of-squares F test) (Fig. 3B). Similarly, the 
ETP50 for erlotinib-treated animals was 30% lower than that of their 
vehicle-treated siblings (F1,834 = 4.9, P < 0.05 by extra sum-of-
squares F test) (Fig. 3C). These results demonstrate that TGFa over-
expression increases arousal threshold, whereas inhibition of EGFR 
signaling decreases arousal threshold, consistent with modulation 
of a sleep state.
EGFR signaling is required for homeostatic regulation 
of sleep
Sleep is postulated to be controlled by two processes: a homeostatic 
process that increases during wakefulness and dissipates during sleep 
and a circadian process that controls when sleep occurs during the 
24-hour day/night cycle (9). While invertebrate studies have demon-
strated a role for EGFR signaling in promoting sleep (12, 13), it is 
unknown whether it does so as part of the homeostatic or circadian 
process. To distinguish between these possibilities, we first tested 
whether EGFR signaling is required for circadian regulation of sleep 
by entraining WT animals in a 14-hour light/10-hour dark cycle until 
5 dpf and then treating animals with either gefitinib or dimethyl 
sulfoxide (DMSO) vehicle control while monitoring their behavior 
in either constant light or constant dark (fig. S4, A to D). While 
gefitinib treatment decreased sleep compared to controls, the circa-
dian pattern of sleep was maintained with no obvious effect on circa-
dian period length or phase, suggesting that EGFR signaling is not 
necessary for circadian regulation of sleep.
To explore the role of EGFR signaling in homeostatic regulation 
of sleep, we developed a large-scale sleep deprivation (SD) assay. We 
monitored the behavior of at least 60 animals from 5 to 8 dpf in a 96-well 
plate that was cut in half. On the beginning of the third night of the 
assay (7 dpf), we disrupted the sleep of half the animals using acoustic 
stimuli (see Materials and Methods) in the dark for 6 hours while 
leaving the other half of the 96-well plate in the video tracker as a 
nonperturbed control. Light was kept off during the remaining 4 hours 
of night and the following day to avoid masking effects of light on any 
recovery sleep (RS) response. We observed a significant increase in sleep 
during the remaining 4 hours of night for perturbed animals compared 
to nonperturbed sibling controls (fig. S5, A to C), similar to the RS 
observed in other species in response to SD. This increase in sleep 
D
J
L
H
F
B
Gefitinib (n = 226)
A
C
G
E
I
K
Fig. 2. Loss of EGFR signaling decreases sleep. (A to D) egf−/−; tgfa−/− animals 
were more active during the day and slept less during the day and night than 
egf+/+; tgfa−/− siblings. Larvae were generated by mating egf+/−; tgfa+/− to egf+/−; 
tgfa−/− animals. For clarity, data for other genotypes are not shown. (E to H) egfra−/− 
animals were more active during the day and slept less during the day and night 
than egfra+/+ siblings. (I to L) Gefitinib-treated WT animals were more active and 
slept less during the day and night than their dimethyl sulfoxide (DMSO)–treated 
siblings. Pooled data from nine (A to D), eight (E to H), and six (I to L) experiments 
are shown. Bar graphs show mean ± SEM. n = number of animals. *P ≤ 0.05, 
**P < 0.01, and ***P < 0.005 for indicated comparisons by one-way ANOVA and 
Holm-Sidak test (A to H) or Student’s t test (I to L).
 o
n
 N
ovem
ber 15, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Lee et al., Sci. Adv. 2019; 5 : eaax4249     13 November 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
5 of 17
persisted during the following subjective day (fig. S5A) but returned 
to normal levels by the following night (fig. S5D). To verify that the 
increased RS resulted from SD and not simply fatigue or some other 
response to the stimulus, we applied the same acoustic stimulation 
to developmentally identical siblings during the day, when the ani-
mals spend most of their time awake (fig. S5E). We observed no 
increase in sleep in perturbed animals compared to nonperturbed 
sibling controls following daytime perturbation (fig. S5, E to H), 
consistent with the increased sleep observed following perturbation 
at night being due to loss of sleep. We calculated a normalized sleep 
rebound value for each animal as the amount of sleep during the 
first 4 hours of RS divided by the average amount of sleep of all 
nonperturbed controls during this time period. Normalized sleep 
rebound was significantly higher in animals perturbed during the 
night, when zebrafish spend most of the time asleep, compared to 
those perturbed during the day, when zebrafish spend most of the 
time awake (fig. S5I), as expected for a perturbation that specifically 
disrupts sleep. These results indicate that this SD assay is both specific 
and robust in its ability to detect a homeostatic response to SD.
We next used this assay to test whether EGFR signaling is required 
for homeostatic regulation of sleep. To do so, we sleep-deprived 
WT siblings treated with either the EGFR inhibitor gefitinib or 
DMSO vehicle control in neighboring video trackers for 6 hours at 
night and quantified sleep rebound during the remaining 4 hours of 
night (Fig. 3, D to G). We observed a 28% reduction in normalized 
sleep rebound for gefitinib-treated animals compared to DMSO- 
treated controls (median response = 1.15 for gefitinib versus 1.59 
for DMSO, P < 0.01, Mann-Whitney test; Fig. 3G and fig. S5, J to O). 
This result indicates that the amount of rebound sleep following SD 
is reduced in gefitinib-treated animals compared to DMSO-treated 
controls and, thus, that EGFR signaling participates in the homeo-
static regulation of sleep.
0.6
A
D
E F G
JIH
B C
Baseline sleep
Night NightDay
6 hours 4 hours
Night Night Night NightDayDay DayDay
(n = 150)
Ge
(n = 162)Perturbed
Control (n = 144)
Perturbed
Control (n = 167)
Fig. 3. EGFR signaling regulates arousal threshold and sleep homeostasis. Representative stimulus response curves for Tg(hs:tgfa) animals and their WT siblings fol-
lowing HS (A), gefitinib and DMSO vehicle-treated WT siblings (B) and erlotinib and DMSO vehicle-treated WT siblings (C). Data points indicate mean ± SEM fraction of 
animals that responded to the stimulus. Dashed lines mark ETP50 values. (A) Tg(hs:tgfa) animals had an ETP50 value of 22.2 versus 6.3 for WT siblings (252% increase; 
F1,834 = 20.95, P < 0.0001 by extra sum-of-squares F test). (B) Gefitinib-treated animals had an ETP50 of 2.7 versus 4.3 for DMSO-treated siblings (37% decrease; F1,834 = 18.16, 
P < 0.0001 by extra sum-of-squares F test). (C) Erlotinib-treated animals had an ETP50 of 3.5 versus 5.0 for DMSO-treated siblings (30% decrease; F1,834 = 4.9, P < 0.05 by 
extra sum-of-squares F test). a.u., arbitrary units. n = number of animals. (D) SD paradigm. (E and F) Sleep behavioral traces for animals treated with DMSO (E) or gefitinib 
(F) starting at 5 dpf, subjected to SD during the first 6 hours of the night at 7 dpf (P; orange), and monitored thereafter in the dark. The 4-hour periods of RS (purple) are 
indicated with dashed boxes. (G) Normalized sleep rebound in DMSO- or gefitinib-treated siblings following SD. Normalized sleep rebound = amount of sleep for each 
perturbed animal during the first 4 hours of RS divided by the average amount of sleep of all nonperturbed controls during this time period. (H to J) After a 1-hour HS in 
the middle of the day (yellow bar), Tg(hs:tgfa) animals showed increased daytime and nighttime sleep for ~24 hours (H and I), followed by decreased sleep (H and J). Sleep 
in (I) and (J) is quantified for the boxed regions in (H), which includes the entire night and the last 3 hours of each day. Pooled data from five (D to G) and two (H to J) ex-
periments are shown. Black, white, and hatched bars under behavioral traces indicate night (10 hours), day (14 hours), and subjective day (14 hours), respectively. 
n = number of animals. **P < 0.01 and ***P < 0.001 by Mann-Whitney test.
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If EGFR signaling regulates sleep homeostasis, then sleep induced 
by activation of EGFR signaling might be followed by a period of 
decreased sleep. When TGFa overexpression was induced in the 
middle of the day, we observed an initial increase in sleep that persisted 
for ~24 hours (day, P < 0.001; night, P < 0.001, two-way ANOVA 
with Holm-Sidak test; Fig. 3, H and I), followed by a decrease in sleep 
(P < 0.001, two-way ANOVA with Holm-Sidak test; Fig. 3, H and J) 
compared to sibling controls. These data are consistent with the hy-
pothesis that EGFR signaling regulates sleep homeostasis.
TGFa overexpression–induced sleep is primarily mediated 
by EGFRa
To investigate the cellular mechanism through which TGFa pro-
motes sleep, we first asked which cells in the brain are activated by 
TGFa overexpression by performing ISH using a probe for c-fos, a 
marker of neural activity (36). We used Tg(hs:tg f a) animals and 
their WT siblings fixed 4 hours after a midday HS, when Tg(hs:tgfa) 
animals sleep ~100% more than their WT siblings (Fig. 4A). We 
observed that tg fa overexpression resulted in strong c-fos expression 
in juxtaventricular cells (Fig. 4C), similar to the expression pattern 
of egfra (Fig. 1A″). In contrast, only low levels of c-fos expression were 
present in identically treated WT siblings (Fig. 4B), indicating that 
the strong c-fos expression in Tg(hs:tg fa) animals was not due to the 
HS. Double fluorescence ISH (FISH) confirmed that TGFa overex-
pression induced c-fos expression in egfra-expressing juxtaventricular 
cells (Fig. 4, D and D′). This result is consistent with the hypothesis 
that TGFa overexpression–induced sleep is mediated, at least in 
part, by egfra-expressing juxtaventricular cells in the brain.
To test this hypothesis, we compared the behavioral effects of 
TGFa overexpression on sleep in egfra−/− and egfra+/+ siblings. We 
found that Tg(hs:tg fa); eg fra+/+ animals slept 270% more than their 
egfra+/+ siblings after HS-induced TGFa overexpression (P < 0.0001, 
two-way ANOVA, Holm-Sidak test; Fig. 4, E and G). These effects 
were strongly suppressed in Tg(hs:tg fa); egfra−/− animals compared 
to their egfra−/− siblings (P = 0.42, two-way ANOVA with Holm-Sidak 
test; Fig. 4, F and G). This result indicates that TGFa overexpression– 
induced sleep is largely mediated by EGFRa. Consistent with this result, 
TGFa overexpression–induced c-fos expression was significantly 
reduced in egfra−/− animals (Fig. 4, H to L). Together, these data 
suggest that EGFR ligands promote sleep primarily by activating 
egfra-expressing juxtaventricular cells in the brain.
Inhibition of MAPK/ERK signaling suppresses  
EGFR-induced sleep
EGFR can act via multiple signal transduction pathways, but genetic 
(13) and pharmacological (37) studies in Drosophila suggest that 
EGFR signaling promotes sleep, at least in part, via MAPK/ERK sig-
naling. To test whether the MAPK/ERK pathway is required for 
EGFR-mediated sleep in zebrafish, we treated Tg(hs:tgfa) larvae im-
mediately after HS with either of two MEK1/2 (MAPK kinase 1/2) 
antagonists previously demonstrated to be effective in zebrafish 
(38). While these antagonists had no effect on sleep or activity in 
WT animals at the concentrations tested, Tg(hs:tg fa) animals treated 
with either 3 M SL327 (fig. S6, A to F) or 15 M U0126 (fig. S6, G 
to L) were significantly more active and slept less after HS than 
vehicle-treated Tg(hs:tg fa) siblings (P < 0.001, two-way ANOVA, 
Holm-Sidak test), although they were still less active and slept more 
than their drug-treated WT siblings (P < 0.001, two-way ANOVA, 
Holm-Sidak test). SL327 treatment reduced both the number and 
length of sleep bouts in Tg(hs:tg fa) animals, while U0126 treatment 
only reduced the number of sleep bouts (fig. S6, C, F, I, and L), possi-
bly because SL327 had a more potent effect on behavior than U0126. 
Thus, both MEK1/2 antagonists suppressed TGFa overexpression– 
induced sleep, suggesting that EGFR signaling regulates sleep, in 
part, via the MAPK/ERK pathway in zebrafish. These results link 
previous independent observations describing changes in ERK sig-
naling following EGFR-induced sleep in Drosophila (13) and a role 
for ERK in regulating invertebrate and vertebrate sleep (37, 39).
TGFa overexpression–induced sleep is suppressed by 
mutation of npvf
In C. elegans, EGF overexpression and cellular stress induce sleep by 
activating EGFR in the ALA interneuron (12). Several RFamide 
family neuropeptides are expressed at high levels in the ALA 
neuron, including flp-13 and flp-24, and overexpression of these 
peptides is sufficient to induce sleep (21). It has been reported that 
EGF-induced sleep is attenuated by ~50% in flp-13 mutants (22) or 
in flp-13; flp-24 double mutants (21) and that heat stress–induced 
sleep in Drosophila is suppressed in mutants that lack the RFamide 
family neuropeptide fmrfamide or its receptor (40). These observa-
tions suggest that RFamide neuropeptides mediate the sedating effects 
of EGFR signaling in these invertebrate species. We recently showed 
that the vertebrate RFamide neuropeptide VF (NPVF), a possible 
homolog of flp-13 and fmrfamide, is necessary and sufficient to pro-
mote sleep in zebrafish (35), similar to our present findings for EGFR 
signaling. On the basis of these observations, we hypothesized that 
EGFR signaling promotes sleep, in part, via NPVF signaling in zebrafish. 
We tested this hypothesis by overexpressing TGFa in npvf-mutant 
animals (35). We found that TGFa-overexpressing animals slept 
450% more than their nontransgenic siblings in control npvf+/− an-
imals (P < 0.0001, two-way ANOVA, Holm-Sidak test; Fig. 5E and 
fig. S7K), similar to the effect of TGFa overexpression in WT ani-
mals (Fig. 1, E to H). However, TGFa overexpression–induced 
sleep was suppressed by 50% in npvf−/− animals compared to TGFa 
overexpression–induced sleep in their npvf+/− siblings (P < 0.0001, 
two-way ANOVA, Tukey’s post hoc test; Fig. 5E and fig. S7K). This 
result suggests that NPVF signaling plays a key role in mediating 
EGFR signaling–induced sleep in zebrafish, consistent with obser-
vations in Drosophila (40) and C. elegans (21, 22).
Because loss of npvf suppressed EGFR-induced sleep, we hypothe-
sized that NPVF signaling acts downstream of EGFR to regulate 
normal levels of sleep. To test this hypothesis, we assayed sleep in 
egfra mutants in the presence or absence of RF9, a small-molecule 
inhibitor of NPFFR1 and NPFFR2, receptors for the mature RFRP1 
and RFRP3 peptides derived from the NPVF prepropeptide (41). If 
EGFR signaling and NPVF signaling act independently to promote 
sleep, then inhibition of both pathways should result in an additive 
effect on sleep. Alternatively, if NPVF signaling acts downstream of 
EGFR, inhibiting both pathways should not have an additive effect. 
We found that egfra−/− animals treated with DMSO vehicle control 
slept significantly less than their egfra+/+ and egfra+/− siblings during 
the day (Fig. 5F), as expected. RF9 treatment also decreased sleep in 
egfra+/+ and egfra+/− animals (Fig. 5F), as previously reported (35). 
However, RF9 treatment did not further decrease sleep in egfra−/− 
animals compared to egfra−/− animals treated with DMSO vehicle 
control (Fig. 5F). These results are consistent with the hypothesis 
that NPVF signaling acts downstream of EGFR signaling to promote 
normal sleep levels.
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EGFR signaling regulates NPVF expression
While genetic experiments in C. elegans (21, 22) and Drosophila 
(40) and our experiments in zebrafish suggest that EGFR signaling 
promotes sleep via RFamide neuropeptides, it is unknown how the 
EGFR and RFamide neuropeptide systems interact. One possibility 
is that EGFR signaling regulates expression of RFamide neuropeptides. 
We tested this hypothesis by assaying NPVF mRNA and protein 
levels in response to gain or loss of EGFR signaling. Using ISH, we 
found that overexpression of TGFa increased npvf mRNA level in 
endogenous npvf-expressing neurons by 68% compared to WT sib-
lings (P < 0.05, two-way ANOVA, Holm-Sidak test; fig. S7, A and 
B). Conversely, treatment with the EGFR antagonist gefitinib decreased 
npvf mRNA level in these neurons by 19% (P < 0.05, Student’s t test; 
fig. S7, C and D). Similarly, using an NPVF-specific antibody (42), 
we found that TGFa overexpression increased NPVF protein level 
in the hypothalamus by 57% compared to WT siblings (P < 0.005, 
two-way ANOVA, Holm-Sidak test; Fig. 5, A and B), while gefitinib 
treatment decreased NPVF protein level by 17% compared to DMSO- 
treated siblings (P < 0.01, Student’s t test; Fig. 5, C and D). In con-
trast, overexpression of the sleep-promoting neuropeptide Y (NPY) 
(43) or the wake-promoting neuropeptide Hcrt (28) did not affect 
NPVF protein levels (fig. S7, E to H). In addition, TGFa overexpres-
sion did not affect Hcrt protein levels (fig. S7, I and J). These results 
suggest that EGFR signaling regulates sleep by specifically regulat-
ing expression of NPVF.
EGFR signaling modulates the activity of  
npvf-expressing neurons
We previously showed that optogenetic and chemogenetic stimula-
tion of npvf-expressing neurons is sufficient to induce sleep (35), 
suggesting that, in addition to affecting NPVF expression, EGFR 
signaling may also promote sleep by stimulating npvf-expressing 
neurons. To test this hypothesis,  we generated Tg(npvf: 
GCaMP6s-T2A-tdTomato) animals, in which npvf-expressing neu-
rons express stoichiometric levels of GCaMP6s and tdTomato (44). 
We used GCaMP6s to monitor calcium levels, a proxy for neuronal 
A
E
H J K LI
F G
B C D D′
4 hours after HS
Fig. 4. TGFa overexpression–induced sleep requires EGFRa. (A) Total sleep induced following TGFa overexpression quantified during the fourth hour after HS. (B and 
C) c-fos expression in a Tg(hs:tgfa) brain at 4 hours after HS shows activation of juxtaventricular cells in the telencephalon, hypothalamus, and hindbrain (arrowhead) (C), 
but not in the brain of an identically treated WT sibling (B). (D and D′) Double FISH of a Tg(hs:tgfa) brain fixed at 4 hours after HS shows coexpression of egfra and c-fos in 
juxtaventricular cells. Boxed region in (D) is magnified in (D′). Images are 2.9-m-thick (D) and 0.7-m-thick (D′) confocal sections. (E to G) TGFa overexpression increased 
sleep in transgenic animals compared to nontransgenic siblings in egfra+/+, but not in egfra−/− animals (red comparisons) (G). TGFa overexpression–induced sleep was 
significantly decreased in egfra−/− animals compared to egfra+/− and egfra+/+ (black comparisons) (G). Yellow bars indicate HS. Pre- and post-HS data are calculated for the 
day of HS. Data are obtained from six pooled experiments. Bar graphs show mean ± SEM. n.s., not significant. (H to L) Juxtaventricular c-fos expression that is induced by 
TGFa overexpression (white arrowheads) is suppressed in egfra−/− animals (J and K) compared to egfra+/+ animals (H and I) at 4 hours after HS. Hindbrain (Hb)–boxed regions 
in (H) and (J) are magnified in (I) and (K). (L) Quantification of c-fos expression in hindbrain and hypothalamus egfra-expressing cells [boxed regions in (H) and (J)]. Data 
points represent single brains. n = number of animals. *P < 0.05 and ***P < 0.005 by two-way ANOVA with Holm-Sidak test. Te, telencephalon; Hb, hindbrain. Scale bars, 30 m.
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activity, in npvf-expressing neurons and normalized GCaMP6s fluo-
rescence intensity values to tdTomato fluorescence to correct for any 
changes in transgene expression or movement artifacts during live 
imaging. To test the hypothesis that EGFR signaling is sufficient to 
stimulate npvf-expressing neurons, we mated Tg(npvf:GCaMP6s- 
T2A-tdTomato) to Tg(hs:tgfa)/+ fish, imaged GCaMP6s and tdTomato 
in 5-dpf animals (Fig. 5G), and then used PCR genotyping to identify 
Tg(hs:tg fa) and WT siblings. Control animals not subjected to a HS 
displayed no difference in GCaMP6s/tdTomato fluorescence between 
Tg(hs:tg fa) and WT siblings (Fig. 5H). However, at 2 hours after HS, 
Tg(hs:tg fa) animals displayed significantly higher levels of GCaMP6s/
tdTomato fluorescence compared to WT siblings (P < 0.005, two-
tailed Wilcoxon matched-pairs signed-rank test; Fig. 5I), suggesting 
that TGFa overexpression stimulates npvf-expressing neurons.
We next tested whether EGFR signaling is necessary for normal 
activity levels of npvf-expressing neurons by inhibiting EGFR sig-
naling. We first quantified baseline GCaMP6s/tdTomato fluorescence 
levels in Tg(npvf:GCaMP6s-T2A-tdTomato) animals. We then treated 
animals with either gefitinib or DMSO vehicle control and reimaged 
the same neurons 90 min later. Last, we calculated normalized 
GCaMP6s/tdTomato fluorescence values by dividing posttreatment 
values by baseline values. Consistent with the TGFa overexpression 
result, we found that inhibition of EGFR signaling using gefitinib 
treatment decreased normalized GCaMP6s/tdTomato fluorescence 
values compared to DMSO-treated siblings (P < 0.05, two-tailed 
Wilcoxon matched-pairs signed-rank test; Fig. 5J). This result sug-
gests that EGFR signaling is required to maintain normal activity 
levels of npvf-expressing neurons. Together, these observations 
suggest that EGFR signaling promotes sleep, at least in part, by 
stimulating npvf-expressing neurons. More broadly, our results in-
dicate that EGFR signaling promotes sleep via RFamide neuropep-
tides in both invertebrates and vertebrates.
C D F
JIH
G
A B E
After HS
Fig. 5. EGFR signaling promotes sleep via NPVF. (A to D) Larval zebrafish schematic. Red box indicates hypothalamic region shown in (A), (C), and (G). Immunostaining 
with an NPVF-specific antibody reveals higher NPVF protein levels at 2 hours after HS for Tg(hs:tgfa) animals compared to WT siblings (A and B) and lower NPVF protein 
levels in animals fixed at 3 hours after treatment with gefitinib compared to DMSO-treated controls (C and D). Representative images are shown in (A) and (C), and average 
pixel intensity of NPVF labeling is quantified in (B) and (D); each dot represents one animal. (E) TGFa-induced sleep was partially suppressed in npvf−/− animals compared 
to npvf+/− siblings. Animals were heat-shocked at 3 p.m. Pre- and post-HS quantify sleep for the day of HS. (F) egfra−/− animals slept less than their egfra+/+ siblings (black 
comparison), and RF9 suppressed sleep in egfra+/+ animals compared to DMSO-treated egfra+/+ siblings (blue comparison), but RF9 treatment did not further decrease 
sleep in egfra−/− animals compared to DMSO-treated egfra−/− siblings (red comparison). RF9 was added on the afternoon of 5 dpf, and sleep was quantified during the day 
at 6 and 7 dpf. (G) Representative images from a Tg(npvf:GCaMP6s-p2A-tdTomato) animal. An individual NPVF neuron is indicated with a white circle. (H) No difference in 
GCaMP6s/tdTomato values was observed between non–heat-shocked Tg(hs:tgfa) and WT siblings. (I) GCaMP6s/tdTomato values were significantly increased in Tg(hs:tgfa) 
animals compared to WT siblings at 2 hours after HS. (J) Normalized GCaMP6s/tdTomato values were significantly decreased in WT gefitinib-treated animals compared 
to DMSO-treated siblings. Normalized GCaMP6s/tdTomato = GCaMP6s/tdTomato value in each neuron at 2 hours after the addition of either gefitinib or DMSO divided 
by the value in the same neuron before treatment is shown. Bar graphs (E and F) and lines (B and D) indicate mean ± SEM. Numbers in parentheses indicate number of 
animals (E and F) or neurons (H to J). *P < 0.05, **P < 0.01, and ***P < 0.001 by two-way ANOVA with Holm-Sidak test (E and F) or by two-tailed Wilcoxon matched-pairs 
signed-rank test (H to J). Scale bars, 20 m.
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Common genetic variants at EGFR signaling–associated 
genes affect human sleep
Having shown that regulation of sleep by EGFR signaling is con-
served between invertebrate and vertebrate animal models, we next 
asked whether this conservation extends to humans. We tested for 
an association between self-reported sleep traits and genetic variation 
in EGFR signaling–associated gene regions in participants of European 
ancestry from the U.K. Biobank (tables S1 and S2) (24). ERBB4 is a 
member of the ERBB family of receptor tyrosine kinases that can 
heterodimerize with ERBB1/EGFR and can be activated by EGF 
family ligands (45) and thus participates in EGFR signaling. We 
found that genetic variation (rs7607363 G allele) at the ERBB4 
genomic locus is associated with increased frequency of excessive 
daytime sleepiness (EDS) (P = 8.00 × 10−9, linear regression analysis; 
Fig. 6, A and B, and table S1). We also found that genetic variation 
(rs1846644 C allele) at the genomic locus of kinase suppressor of ras 
2 (KSR2), a scaffolding protein with established roles in EGFR/
MAPK signaling (46), is associated with increased sleep duration 
(P = 5.30 × 10−9, linear regression analysis), increased frequency of 
daytime napping (P = 2.00 × 10−41, linear regression analysis), and 
increased frequency of EDS (P = 2.50 × 10−27, linear regression 
analysis) (Fig. 6, A and C to E, and table S1). In addition, pathway 
analysis for EDS revealed associations at EGFR signaling pathways 
enriched in the sleep propensity subtype of daytime sleepiness (4). 
Together, these results suggest that the identified genetic variants in 
the ERBB4 and KSR2 loci associate with measures of increased sleep.
Expression quantitative trait loci (eQTL) analysis of the ERBB4 
variant rs7607363 showed increased ERBB4 expression associated 
with the minor allele that is associated with increased sleep (fig. S8A) 
and no association with expression levels of neighboring genes, sug-
gesting a gain of function associated with this single-nucleotide 
polymorphism (SNP). The lead SNPs in the ERBB4 and KSR2 loci, 
as well as several SNPs highly linked to the lead SNPs, are aligned 
within each gene, with recombination hotspots separating them 
from neighboring genes (Fig. 6, B to E). These observations provide 
supporting evidence that the SNPs are linked to ERBB4 and KSR2. 
However, since SNPs may influence distant genes, we cannot be 
absolutely certain that ERBB4 or KSR2 is the causal gene at each 
locus. Despite this caveat, these results suggest that common vari-
ants in EGFR signaling pathway components underlie some of the 
natural variation observed in human sleep.
To validate the association of KSR2 and ERBB4 with sleep traits 
in vivo, we treated zebrafish with small-molecule inhibitors of these 
proteins (fig. S8). First, we treated WT zebrafish with APS-2-79 (fig. 
S8, J to Q), a small molecule that stabilizes KSR2 in an inactive state 
(46). Treatment with this drug resulted in decreased sleep during 
both the day (−38%) and night (−14%) compared to DMSO vehicle- 
treated controls (day, P < 0.05; night, P < 0.005, Student’s t test; 
fig. S8, M and N). These effects were primarily due to shorter sleep 
bouts at night and a trend of higher activity and waking activity 
during the day (fig. S8, J to L and P). This phenotype is consistent 
with the finding that Ksr2 knockout mice exhibit increased locomotor 
activity (47). Next, we treated WT zebrafish with spironolactone 
(fig. S8, B to I), an ERBB4 small-molecule inhibitor (48). Treatment 
with this drug resulted in a 7% increase in locomotor activity and 
a 34% decrease in sleep during the day (activity, P < 0.05; sleep, 
P < 0.01, Student’s t test), with no significant effect at night, com-
pared to DMSO vehicle-treated siblings (fig. S8, B, C, E, and F). 
These phenotypes were associated with higher waking activity and 
fewer sleep bouts during the day (fig. S8, D and G). Thus, inhibition 
of KSR2 or ERBB4 phenocopies loss of EGFR signaling, although 
the spironolactone result should be interpreted with caution because 
this drug has been shown to also target other proteins (48). These 
results validate a genetic pathway that underlies some of the ob-
served variation in human sleep quality and quantity.
DISCUSSION
There is abundant evidence that sleep is behaviorally conserved 
throughout evolution (9), and genetic mechanisms that regulate 
sleep have been described in both vertebrate and invertebrate species 
(9). However, while it has been shown that genes that regulate circadian 
rhythms and thus affect sleep timing are conserved in invertebrates 
and humans (1, 9), there is relatively little clear and unambiguous 
evidence for conserved mechanisms that regulate sleep in both ver-
tebrates and invertebrates, including humans. As a result, the extent 
to which mechanisms that underlie sleep evolved independently in 
vertebrates and invertebrates remains unclear. Identifying such 
mechanisms is important not only from an evolutionary standpoint 
but also because these mechanisms would likely play a central role 
in regulating sleep in all organisms. Here, we describe a genetic 
mechanism that regulates sleep in both invertebrates and vertebrates 
and provide evidence that these findings may extend to humans.
We report that EGFR signaling regulates sleep in the zebrafish, a 
diurnal vertebrate. We found that TGFa overexpression increased 
sleep, whereas mutation of EGFR or its ligands, or pharmacological 
inhibition of EGFR signaling, decreased sleep. The reduced sleep re-
sulting from inhibition of EGFR signaling was due to defects in both 
initiation and maintenance of sleep, consistent with the human 
sleep disorder insomnia. While gain- and loss-of-function studies 
have shown that EGFR signaling is both necessary and sufficient for 
normal sleep levels in C. elegans and Drosophila (12, 13, 16), our 
results extend these invertebrate studies by demonstrating that this 
mechanism is conserved in a vertebrate and identify a previously 
undescribed role of EGFR signaling in regulating sleep homeostasis. 
In both zebrafish and Drosophila (13), animals with elevated EGFR 
signaling had more and longer sleep bouts, whereas pharmacological 
inhibition of EGFR signaling resulted in shorter sleep bouts, indi-
cating that EGFR signaling promotes consolidation of the sleep state. 
Combined with our discovery that common variants in two genes 
that participate in EGFR signaling are associated with variation in 
human sleep, this study provides one of the first clear examples of a 
mechanism that regulates sleep in both invertebrate and vertebrate 
species and suggests that these findings may extend to humans. 
These results reveal a clear evolutionary link between invertebrate 
and vertebrate sleep, suggest that EGFR signaling participates in an 
ancient and central sleep regulatory mechanism, and provide a basis 
to explore central and ancient mechanisms that regulate vertebrate 
sleep.
In contrast to our findings using zebrafish and previous invertebrate 
studies (12, 13, 16, 19), the role of EGFR signaling in mammalian 
sleep is unclear. While EGFR signaling has been shown to regulate 
various rodent behaviors (14, 15), attempts to explore its requirement 
for sleep have been confounded by the embryonic lethality of murine 
Egfr-null mutants (32). Consistent with a role for EGFR signaling in 
rodent sleep, one study using mice homozygous for the Egfrwa2 hy-
pomorphic allele, which produces a receptor with reduced tyrosine 
kinase activity, observed increased daytime locomotor activity (14). 
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Fig. 6. Genetic variants at KSR2 and ERBB4 associate with human sleep quality and quantity. (A) Forest plot of associations between genetic variant rs7607363 in 
ERBB4 and rs1846644 in KSR2 with sleep quality and quantity measures. Black boxes indicate effect estimate, and gray lines represent 95% confidence interval. Data are 
based on 453,964 human subjects of European ancestry in the U.K. Biobank. Full results for each single-nucleotide polymorphism (SNP) are shown in table S1. (B) Regional 
association plot for genome-wide significant association between ERBB4 rs7607363 and EDS. (C to E). Regional association plots for genome-wide significant association 
between KSR2 rs1846644 and sleep duration (C), EDS (D), and daytime napping (E). Genes within each region are shown in the lower panels. Blue lines indicate recombi-
nation rate. Filled circles show the −log10 P value for each SNP, with the named SNP shown in purple. Additional SNPs in the locus are colored according to correlation (r2) 
with the lead SNP, estimated by LocusZoom based on the CEU HapMap haplotypes. Dashed lines represent the genome-wide significance threshold (P < 5 × 10−8).
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However, this allele contains a linked hypomorphic mutation in Wnt3a 
(14) that may confound sleep studies. Wnt signaling is required for 
brain development (49) and has been implicated in regulating sleep 
duration in Drosophila (18). Mice lacking TGFa or EGF are viable 
and fertile, but sleep studies using these mutants have not been de-
scribed. Reports of EGFR gain-of-function manipulations on mammalian 
sleep are also inconclusive. Acute intracerebroventricular injection 
of EGF into rabbits was sufficient to increase sleep (20), although the 
effect required the use of high EGF levels that are unlikely to be 
physiologically relevant. In contrast, infusion of TGFa had no effect 
on sleep duration in hamsters, although it did suppress wheel running 
(14, 15). These conflicting gain-of-function results could be due to 
the use of small numbers of animals, nonphysiological peptide con-
centrations resulting in nonspecific behavioral effects, or the use of 
in vitro synthesized peptides that may lack posttranslational modi-
fications required for function. Other indirect evidence supporting 
a role for EGFR signaling in mammalian sleep was provided by the 
recent finding that inhibition of ERK results in reduced sleep in ro-
dents (39). However, ERK participates in many signal transduction 
pathways, so it is unclear whether this effect is specific to EGFR sig-
naling. Thus, before our study, it remained unclear whether EGFR 
signaling plays a role in vertebrate sleep.
Consistent with a conserved role for EGFR in sleep is its expression 
in the hindbrain and hypothalamus in both rodents and zebrafish. 
These brain structures are anatomically and molecularly conserved in 
mammals and zebrafish (10) and play prominent roles in sleep regula-
tion (50). In rodents, Egfr is expressed in juxtaventricular radial-
glial– like cells named tanycytes (51), which are responsive to photoperiod 
and regulate energy balance (52), and Tgfa is expressed in nearby 
ependymal cells (27, 53). Similarly, in zebrafish, egfra is expressed in 
juxtaventricular cells that express the glial cell markers sox2 and glial 
fibrillary acidic protein, and tg fa is expressed in an adjacent sox2- 
expressing glial cell population. These observations suggest a con-
served neuroanatomical basis for Tgfa/Egfr-regulated sleep. This 
possibility is supported by the observations that TGFa overex-
pression in zebrafish results in c-fos expression in egfra-expressing 
juxtaventricular cells, while intracerebroventricular injection of either 
TGFa or EGF in hamsters similarly results in ERK activation in Egfr- 
expressing juxtaventricular tanycytes (15, 51). Studies in mammals 
have shown that these tanycytes can sense and transport molecules 
from the cerebrospinal fluid (CSF) to brain regions implicated in reg-
ulating sleep (54) and that CSF contains sleep-inducing factors (55). 
Together, these observations suggest that Tgfa/Egfr signaling may reg-
ulate sleep through interactions between CSF, specialized glial cells, 
and neurons. This possibility contrasts with most previously described 
neuropeptidergic and neuromodulatory mechanisms that regulate 
sleep, which act via communication between neurons, but is consistent 
with the model that tanycytes act as gatekeepers that monitor homeo-
static signals in CSF (52), including those that regulate sleep (55).
Before this study, the molecular and cellular mechanisms through 
which EGFR regulates invertebrate sleep were unclear. It has been 
shown that EGF-induced sleep in C. elegans is suppressed by mutation 
of the RFamide neuropeptides flp-13 and flp-24 (21, 22). Likewise, 
in Drosophila, cellular stress–induced sleep, which is thought to be 
mediated by EGFR signaling, is suppressed by mutation of the RFamide 
neuropeptide fmrfamide (40). However, these studies only demon-
strated genetic interactions, and the mechanism linking the EGFR 
and RFamide systems was unknown. We previously showed that NPVF, 
a member of the vertebrate RFamide family of neuropeptides, as well 
as npvf-expressing neurons, are necessary and sufficient for normal 
sleep amount in zebrafish (35), similar to our findings for EGFR sig-
naling in this study. Our demonstration that EGFR signaling promotes 
sleep in part via the NPVF system in zebrafish suggests that this aspect 
of EGFR-regulated sleep is conserved, although it is unclear whether 
the vertebrate and invertebrate RFamide proteins are true orthologs 
owing to low sequence conservation (35). In addition to showing a 
genetic interaction, we found that EGFR signaling regulates both NPVF 
expression and the activity of npvf-expressing neurons, providing a 
molecular and cellular link between the two pathways. However, we 
did not observe egfra expression in npvf-expressing neurons, so it 
remains unclear how EGFR signaling affects NPVF expression and 
the activity of npvf-expressing neurons. One possibility is that egfra 
is expressed in npvf-expressing neurons at levels too low to detect 
using ISH. Alternatively, presently unknown genes and/or neurons 
may act to link the EGFR and NPVF systems. Further studies are also 
needed to determine whether EGFR signaling regulates the expression 
of invertebrate RFamide neuropeptides and the activity of neurons 
that express them, and whether mechanisms that act upstream of EGFR 
signaling to promote invertebrate sleep, such as cellular stress, are 
conserved in vertebrates.
Are these experimental findings in model systems relevant to 
humans? Our analysis of several self-reported sleep traits (N = 450,000) 
in humans of European ancestry from the U.K. Biobank (4–8, 24) 
identified genome-wide significant associations of several sleep traits 
with common variants in the KSR2 and ERBB4 genomic loci. KSR2 
is a scaffolding protein that enables interaction of the EGFR sig-
naling components RAF, MEK, and ERK, and thus is crucial for EGFR 
signaling (46). ERBB4 is a member of the ERBB1/EGFR receptor 
tyrosine kinase subfamily that binds several EGFR ligands and 
forms heterodimers with other ERBB family members, including 
EGFR (45). Our results suggest that common variants in EGFR sig-
naling pathway genes underlie some of the variation observed in human 
sleep, including traits such as sleep duration, daytime napping, and 
EDS, suggesting gain-of-function effects leading to an increased 
sleep propensity. We found that genetic loss of egfra, egf, or tgfa, as 
well as pharmacological inhibition of EGFR, KSR2, or ERBB4, 
results in reduced sleep in zebrafish, consistent with the human data. 
Our results are consistent with a report that elevated TGFa serum 
levels are associated with fatigue in humans (56). Furthermore, our 
results suggest that the disrupted sleep commonly observed in RA-
Sopathies (57), a group of human developmental syndromes caused 
by mutations in genes involved in Ras-MAPK signaling, may be directly 
caused by abnormal EGFR signaling, rather than occurring as a sec-
ondary consequence of abnormal development. Last, we note that 
except for narcolepsy, which is due to loss of Hcrt neurons (1), and 
circadian disorders that affect sleep timing (1), the basis for human 
sleep disorders is largely unknown, and our study provides one of 
the first examples of a genetic mechanism that likely affects human 
sleep. Further studies using animal models, such as zebrafish, will 
provide a deeper mechanistic understanding of the role of EGFR 
signaling in sleep and how abnormal EGFR signaling results in sleep 
disorders.
MATERIALS AND METHODS
Experimental model
Zebrafish experiments and husbandry followed standard protocols 
(58) in accordance with Caltech Institutional Animal Care and Use 
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Committee guidelines. Larval zebrafish were studied before the onset 
of sexual differentiation, and all behavioral experiments were per-
formed using siblings with the same genetic background, differing 
only in the presence of a transgene, mutation of a specific gene, or 
treatment with drugs and appropriate vehicle control. The age of 
animals used in each experiment is described in the manuscript, in 
each figure legend, or in this section. All experiments used animals 
from a TLAB strain. Unless otherwise noted, larvae were raised and 
behaviorally tested in a 14-hour light/10-hour dark cycle, with white 
lights on from 9 a.m. to 11 p.m.
Transgenic and mutant zebrafish
Tg(hs:tgfa)
Zebrafish tg fa complementary DNA (cDNA) was isolated using 5′ and 3′ 
RACE (FirstChoice RLM-RACE, AM1700, Thermo Fisher Scientific), 
and the open reading frame (ORF) was cloned downstream of the 
zebrafish hsp70c promoter (59) in a vector containing flanking I–SceI 
endonuclease recognition sites. We generated stable transgenic an-
imals by injecting plasmids with I–SceI (New England Biolabs Inc.) 
into the cell of embryos at the one-cell stage (60). To identify trans-
genic founders, we outcrossed potential founders, heat-shocked 
their progeny at 5 dpf, fixed animals 30 min later, and performed 
tg fa ISH. At least two lines that produced strong and ubiquitous 
overexpression and lacked pre-HS expression were selected and 
tested for behavioral phenotypes. The two independent Tg(hs:tg fa) 
transgenic lines produced similar behavioral phenotypes, but all 
data in the paper are from the line that produced stronger pheno-
types. Transgenic animals were identified by PCR using the primers 
5′-CGGGCCACCATGATGTAT-3′ and 5′-GGTTTGTC-
CAAACTCATCAATGT-3′ with a product size of 647 base pairs 
(bp).
Tg(npvf:GCaMP6s-2A-tdTomato)
Using Gibson assembly, the 3.9-kb npvf promoter (35) was cloned 
upstream of GCaMP6s (61), a T2A sequence (62), and tdTomato. 
Transgenic lines were generated using the I–SceI method (60).
tgfa mutant
Using TALENs (30), we isolated a zebrafish tg fa mutant that con-
tains a 7-bp deletion (ORF nucleotides 25 to 31: 5′-ACAATAT-3′) 
that shifts the translational reading frame after the eighth amino 
acid and introduces a premature stop codon that should truncate 
the protein from 189 to 61 amino acids (fig. S2A). The predicted 
mutant protein lacks the signal peptide, protease cleavage sites, and 
epidermal growth factor–like domain and should thus be nonfunc-
tional. Tgfa−/− zebrafish are viable, and homozygous mutant males 
and females are fertile, with no gross morphological abnormalities. 
Mutant animals were genotyped using the primers 5′-GACGACGCT-
GAGAATCTTTCATC-3′ and 5′-CAATCGTTTTGGTCTTTGCAT-3′, 
which produce a 188- or 181-bp band for the WT or mutant allele, 
respectively.
egf mutant
Using CRISPR-Cas9 (31), we isolated a zebrafish egf  mutant that 
contains a 19-bp insertion and a 2-bp deletion after ORF nucleotide 
426 that shifts the translational reading frame and introduces a pre-
mature stop codon that should truncate the protein from 1177 to 
457 amino acids (fig. S2B). The predicted mutant protein lacks five 
EGF-like domains and the transmembrane domain and should thus 
be nonfunctional. Egf −/− zebrafish are viable, and homozygous mu-
tant males and females are fertile, with no gross morphological ab-
normalities. Mutant animals were genotyped using the primers 
5′-GCTGTGGATTGTGATCATGC-3′ and 5′-TGCAGAAAAA-
CAGCCTGAAA-3′, which produce a 204- or 221-bp band for the 
WT or mutant allele, respectively.
egfra mutant
Using CRISPR-Cas9 (31), we generated a zebrafish egfra mutant that 
contains an 11-bp deletion and a 27-bp insertion after nucleotide 
position 792 that shifts the translational reading frame and intro-
duces a premature stop codon upstream of the transmembrane and 
intracellular domains, and should thus produce a non-functional 
protein (fig. S2C). egfra−/− animals were viable and lacked obvious 
morphological abnormalities. egfra−/− males were fertile, but eg fra−/− 
females were seemingly infertile. Mutant animals were genotyped 
using the primers 5′-ACTTCCAGGATGAAGGGACA-3′ and 
5′-CTTACGTGGGCATGTCTTGA-3′, which produced a 137- or 
153-bp band for the WT or mutant allele, respectively.
Tg(hs:hcrt) zf12Tg (28), Tg(hs:npy) ct853Tg (43), and npvf ct845 
mutant (35) zebrafish have been previously described.
Zebrafish behavioral assays
Locomotor activity assay
Individual larvae were placed into each well of a 96-well plate (7701-
1651, Whatman) containing 650 l of E3 embryo medium [5 mM 
NaCl, 0.17 mM KCl, 0.33 mM CaCl2, and 0.33 mM MgSO4 (pH 7.4)] 
at 4 dpf and acclimated overnight in the video tracker before behavioral 
analysis beginning at 5 dpf. Plates were sealed with an optical adhesive 
film (4311971, Applied Biosystems) to prevent evaporation, except 
for drug experiments. Animals in unsealed plates can appear to have 
higher amounts of sleep compared to those in sealed plates because 
as water evaporates from each well, it forms a concave meniscus at 
the top of the well, which creates a slight visual distortion that causes 
the tracking system to miss some animal movements. To mitigate 
this issue, each well was filled to the top with water each morning 
during unsealed plate experiments. The sealing process introduces 
air bubbles in some wells, which are discarded from analysis. Animals 
were blindly assigned a position in the plate and were genotyped 
after the behavioral experiment was complete. Locomotor activity 
was monitored using a video tracking system (Viewpoint Life Sciences) 
with a Dinion one-third inch monochrome camera (Dragonfly 2, 
Point Grey) fitted with a fixed-angle megapixel lens (M5018-MP, 
Computar) and infrared filter. For HS-induced overexpression ex-
periments, larvae were heat-shocked at 37°C for 1 hour starting 
at 3 p.m., 4 p.m., or 9:45 p.m. at 5 dpf. The movement of each larva 
was captured at 15 Hz and recorded using the quantization mode 
with 1-min time bins. The 96-well plate and camera were housed 
inside a custom-modified ZebraBox (Viewpoint Life Sciences) that 
was continuously illuminated with infrared LEDs and illuminated 
with white LEDs from 9 a.m. to 11 p.m., except as noted in experi-
ments where animals were entrained in a 14-hour light/10-hour 
dark cycle and then assayed in constant light or constant dark. The 
96-well plate was housed in a chamber filled with recirculating wa-
ter to maintain a constant temperature of 28.5°C. The parameters 
used for detection were as follows: detection threshold, 15; burst, 
29; freeze, 3, which were determined empirically. Data were pro-
cessed using custom PERL and MATLAB (MathWorks Inc.) scripts, 
and statistical tests were performed using Prism (GraphPad) for 
ANOVA analysis and Excel (Microsoft) for Student’s t test.
A movement was defined as a pixel displacement between adjacent 
video frames preceded and followed by a period of inactivity of at 
least 67 ms (the limit of temporal resolution). Any 1-min period with 
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no movement was defined as 1 min of sleep based on arousal threshold 
changes (28). A sleep bout was defined as a continuous string of sleep 
minutes. Sleep latency was defined as the length of time from lights 
on or off to the start of the first sleep bout. Average activity was 
defined as the average amount of locomotor activity in seconds per 
hour, including sleep bouts. Average waking activity was defined 
as the average amount of activity in seconds per hour, excluding 
sleep bouts.
Arousal threshold assay
We used an Arduino-based automated driver to control two sole-
noids (28P-I-12, Guardian Electric) that delivered a tap over an in-
tensity range of 4095 settings (from 0.01 to 40.95) to a 96-well plate 
in the video tracker (35). We used taps ranging from a power setting 
of 1 to 36.31. Taps of 14 different intensities were applied in a random 
order with an intertrial interval of 1 min during the day or night 
for Tg(hs:tg fa) or gefitinib and erlotinib experiments, respectively. 
Previous studies showed that a 15-s intertrial interval is sufficient to 
prevent behavioral habituation (63). The background probability of 
movement was calculated by identifying for each genotype the frac-
tion of animals that moved 5 s before all stimuli delivered during an 
experiment (14 different tap powers × 30 trials at each intensity = 420 
data points per animal). This value was subtracted from the average 
response fraction value for each tap event. The response of larvae to 
the stimuli was monitored using the video tracking software and 
was analyzed using MATLAB and Excel. Statistical analysis was per-
formed using the Variable Slope log(dose) response curve fitting 
module of Prism.
SD assay
At 4 dpf, up to 84 animals were placed in a 96-well plate that had 
been cut into two separable halves that can be rejoined to fit inside 
the video tracker. Animals were monitored for 48 hours (5 to 6 dpf) 
to measure baseline sleep. Experiments in which significant dif-
ferences were observed between the two halves of the plate during 
the 24 hours before perturbation were excluded from analyses. 
Immediately before the start of the third night of analysis (7 dpf), a 
half-plate from each of two video trackers was transferred and fas-
tened to the center of a 245-mm2 square dish (431301, Corning) 
containing 20 glass beads, 6 plastic marbles, and 8 fixed pegs that 
prevent the marbles and beads from only circling the perimeter of 
the plate during nutation. For night-perturbed animals, the plates 
were wrapped in aluminum foil to shield the animals from light, 
fastened to a nutator (B3D1020, Benchmark Mini BioMixer), and 
nutated in a dark 28°C incubator for 6 hours. For day-perturbed 
experiments, animals of the same developmental stage were treated 
the same, except the plates were exposed to light during perturba-
tion during the day at 7 dpf. In addition to mechanical stimulation, 
we simultaneously subjected the animals to auditory stimuli 
by playing songs from a percussive recording in random order 
(Death Magic, Health) at maximum volume using a portable 
Bluetooth speaker (DKnight MagicBox II) that was housed in the 
incubator. For each SD half-plate, the corresponding half remained 
inside the video tracker to serve as a nonperturbed control. At the 
end of the 6-hour perturbation, the SD half-plates were rejoined 
with their nonperturbed control halves in their respective video 
tracker. Night-perturbed samples were kept in the dark when 
transferred from the SD assay into video trackers, and both night- 
and day-perturbed samples were maintained in dark for the rest 
of the experiment to avoid masking effects of light on any sleep 
recovery response.
Behavioral data analysis
sort_fish_sttime_192.pl. is a Perl script (28) that converts data 
acquired by the Viewpoint system to a format that is useful for 
MATLAB analysis. perl_batch_192well.m is a MATLAB script that 
allows the sort_fish_sttime_192.pl. script to run using MATLAB. 
TapAnalysis.m is a MATLAB script that analyzes tapping assay data 
and generates a table that lists the number of animals that moved 
following each tap. VT_analysis.m is a MATLAB script [modified 
from (28)] that performs sleep/wake analyses. These scripts are 
posted online (35), and detailed instructions on their use will be 
provided upon request.
Histology
In situ hybridization
Samples were fixed in 4% paraformaldehyde (PFA) in phosphate- 
buffered saline (PBS) for 16 hours at room temperature. ISH was 
performed using digoxigenin (DIG)–labeled antisense riboprobes 
(DIG RNA Labeling Kit, Roche) (35). Double FISH was performed 
using DIG- and fluorescein-labeled riboprobes and the TSA Plus 
Fluorescein and Cyanine 3 Systems kit (PerkinElmer). Probes spe-
cific for npvf (35) and c-fos (35) have been described. The tg f a probe 
was transcribed using a PCR product amplified from zebrafish 
cDNA using the primers 5′-CGCGTGCCTTCATCTTTATT-3′ 
(forward) and 5′-TCCCACTGCCCATATTGAAC-3′ (reverse) and 
then serially amplified with the same forward primer and a T7 
sequence (lowercase) added to the primer 5′-ggatcctaatacgactcac-
tatagggTCCCACTGCCCATATTGAAC-3′ (reverse). The eg f ra 
probe was transcribed using a PCR product amplified from zebrafish 
cDNA using the primers 5′-TCTGCTTGACCTCCACAGTG-3′ 
(forward) and 5′-CAAGGGCAAAAGTACCTGATCG-3′ (reverse) 
and then serially amplified with the same forward primer and a T7 
sequence (lowercase) added to a reverse primer located within that 
amplicon: 5′-ggatcctaatacgactcactatagggTGTAACAAGCTGAAG-
TAACGTGC-3′. The sox2 probe was transcribed using a PCR product 
amplified from zebrafish cDNA using the primers 5′-GGTCAAC-
CAGAGGATGGACA-3′ (forward) and 5′-AACTGCGTACAGG-
CCACATT-3′ (reverse) and then serially amplified with the inner 
primer 5′-GGCCGACAGCTACGCGCATATGAA-3′ (forward) and 
a T7 sequence (lowercase) added to a primer located within that 
amplicon: 5′-taatacgactcactatagggGCTGGAGAGTGCCTCT-
GTTC-3′.
Immunohistochemistry
Samples were fixed in 2% PFA in PBS overnight at 4°C and then 
washed with 0.25% Triton X-100/PBS (PBTx). Brains were dissected 
and blocked in 2% goat serum/2% DMSO/PBTx overnight at 
4°C. Antibody incubations were performed in blocking solution 
overnight at 4°C using rabbit anti-NPVF (1:200; ab122738, Abcam) 
or rabbit anti-Hcrt (1:500; AB3704, MilliporeSigma) primary anti-
bodies and Alexa Fluor 568 secondary antibody (1:500; Life Tech-
nologies). Samples were mounted in Vectashield (H-1000, Vector 
Labs) and imaged using a Zeiss LSM 780 confocal microscope.
Pharmacology
A dose-response experiment was first performed for each drug to 
determine its optimal concentration. Each drug was dissolved in 
DMSO and then added to E3 medium. The following drug concen-
trations were tested: DMSO vehicle control, 0.1, 0.5, 1, 5, 10, 50, and 
100 M. Gefitinib (13166, Cayman Chemical) and erlotinib (10483, 
Cayman Chemical) were not soluble at 50 or 100 M, and treatment 
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of zebrafish with 10 M of either drug produced developmental de-
fects in a small number of animals. Treatment with 5 M gefitinib 
or erlotinib did not cause developmental defects but did result in 
increased locomotor activity and decreased sleep compared to 
DMSO vehicle-treated controls. Optimal concentrations for other 
drugs were determined in a similar fashion and were used in experiments 
at the following concentrations: 15 M U0126 (1144, Tocris), 3 M 
SL327 (1969, Tocris), 10 M RF9 (3672, Tocris), 0.2 M spironolac-
tone (2968, Tocris), and 5 M APS-2-79 (S8355, Selleck Chemicals). 
Drug solutions were freshly prepared before each experiment. Con-
trols were exposed to DMSO at concentrations identical to experi-
mental conditions, at no more than 0.1% DMSO. Drugs and DMSO 
vehicle were loaded into alternating rows of a 96-well plate or loaded 
on opposite sides of a 96-well plate. WT larvae from the same clutch 
were then added to the plate. For RF9 experiments and gefitinib 
constant dark and constant light experiments, drug and DMSO ve-
hicle were loaded into separate sides of a 96-well plate with an emp-
ty row in between. WT larvae from the same clutch were added to 
the plate, and plates were sealed with an optical adhesive film 
(4311971, Applied Biosystems) to prevent evaporation.
Quantitative polymerase chain reaction
Zebrafish were raised on a 14-hour light/10-hour dark cycle at 
28.5°C with lights on at 9 a.m. and lights off at 11 p.m. At 5 dpf, total 
RNA was collected using TRIzol reagent (15596-026, Life Technologies) 
from 20 pooled larvae per biological replicate every 6 hours for 36 hours, 
with three independent biological replicates at each time point. 
cDNA was synthesized from 5 g of total RNA using SuperScript III 
Reverse Transcriptase (18080-051, Invitrogen), and qPCR was car-
ried out using SYBR Green Master Mix (4364346, Life Technologies) 
using an ABI PRISM 7900HT (Life Technologies) instrument using 
the primers 5′-GTGTGTGGTGGGCAGTGTC-3′ and 5′-CCAA-
CAGGAGAGGGTGTGAC-3′ for tg fa and 5′-ATCCAGAC-
CCCAATACAAC-3′ and 5′-GGGAGACTCTGCTCCTTCT-3′ 
for per1b. ef1a was used as a reference gene using the primers 
5′-CAGCTGATCGTTGGAGTCAA-3′ and 5′-TGTATGCGCT-
GACTTCCTTG-3′. Relative expression levels were determined us-
ing the Ct method (64), normalized to the highest cycle threshold 
(Ct) value for each gene.
Imaging
Dissected brains were coverslip-mounted in Vectashield (H-1000, 
Vector Labs) or 80% glycerol in PBS and imaged using a compound 
microscope [AxioImager with EC Plan-Neofluar 10×/0.30–numerical 
aperture (NA) air objective or Plan-Apochromat 20×/0.8-NA air 
objective, Zeiss] for chromogenic ISH samples or using a confocal 
microscope (LSM 780 with Plan-Apochromat 10×/0.45-NA air ob-
jective, LD LCI Plan-Apochromat 25×/0.8-NA Imm Corr objective, 
or LD C-Apochromat 40×/1.1-NA water objective; Zeiss) for FISH 
samples. Fluorescein and cyanine 3 were imaged in separate channels 
with 488- and 561-nm lasers, respectively. Confocal images were 
displayed as an optical section of approximately 1–airy unit thickness.
For c-fos and npvf mRNA quantification, chromogenic ISH was 
performed using c-fos and npvf riboprobes on 5-dpf dissected 
brains, with experimental and control samples developed in the 
same tube blinded to genotype (Fig. 4, H to L, and fig. S7, A and B) 
or with experimental and control samples developed in different 
tubes in parallel and treated identically (fig. S7, C and D). Samples 
were imaged using a Zeiss compound microscope and then geno-
typed by PCR. Regions of interest (ROIs) were drawn over hypo-
thalamic or hindbrain regions containing ISH signal, along with a 
nonlabeled area of the brain that was selected for background cor-
rection. The ISH signal was quantified using ImageJ (65), with back-
ground subtraction correction. Average pixel intensity within the 
ROI was quantified blind to genotype or treatment.
For NPVF (Fig. 5, A and B, and fig. S7, E to H) and Hcrt (fig. S7, 
I and J) protein quantification, experimental and control brains 
were immunostained in the same tube, imaged using a Zeiss confocal 
microscope, and then genotyped by PCR. For NPVF protein quan-
tification on drug-treated animals (Fig. 5, C and D), experimental 
and control brains were immunostained in different tubes in parallel 
and treated identically. An ROI containing all NPVF soma was drawn 
in each brain hemisphere to calculate mean fluorescence intensity, 
and an unlabeled area in the image was selected for background cor-
rection using ImageJ (65). ROIs were kept the same size and shape 
but moved to contain as many NPVF soma as possible across images. 
Average pixel fluorescence intensity was quantified blind to geno-
type or treatment.
For GCaMP6s experiments, 5-dpf Tg(npvf:GCaMP6s-2A- 
tdTomato) animals were mounted in low-melting agarose and then 
imaged once per minute for 5 min. The average pixel intensity of 
GCaMP6s and tdTomato fluorescence in each neuron was averaged 
for the five time points. tdTomato fluorescence was used to normalize 
GCaMP6s fluorescence to control for movement artifacts or changes 
in transgene expression. For Tg(hs:tg fa) experiments, these animals 
and their WT siblings were either not heat-shocked or heat-shocked 
for 30 min at 37°C and then embedded in agarose 30 min later. Animals 
were imaged 2 hours after heat shock. For gefitinib experiments, animals 
were head-fixed in agarose and imaged, then treated with either 
DMSO or 10 M gefitinib in E3 medium, and then imaged again 
30 min later. A rolling ball algorithm (ImageJ) was used for back-
ground correction. ROIs were drawn over each cell in the red channel, 
and the average pixel intensity of the green channel (GCaMP6s) was 
divided by the average pixel intensity of the red channel (tdTomato). 
NPVF soma with saturated fluorescence were excluded from quan-
tification. Images were quantified blind to treatment or condition.
Human study population and phenotypes
This study was conducted on participants of European ancestry from 
the U.K. Biobank study of more than 500,000 people aged 40 to 69 
living in the United Kingdom (24). We identified two genome-wide 
significant signals that localize within genes broadly implicated in 
EGFR/MAPK signaling using summary statistics of GWAS available at 
the Sleep Disorder Knowledge Portal: http://sleepdisordergenetics.org/ 
(4–8). Self-reported heath questionnaire, anthropometric assessments, 
and demographic information were collected at baseline. To assess 
chronotype, subjects were asked, “Do you consider yourself to be…” 
with response options “Definitely a ‘morning’ person,” “More a 
‘morning’ than ‘evening person,” “More an ‘evening’ than a ‘morning’ 
person,” “Definitely an ‘evening’ person,” “Do not know,” and “Prefer 
not to answer,” which were coded as 2, 1, −1, −2, 0, and missing, re-
spectively. To assess difficulty waking up, participants were asked, 
“On an average day, how easy do you find getting up in the morn-
ing?” with responses “Not at all easy,” “Not very easy,” “Fairly easy,” 
“Very easy,” “Do not know,” and “Prefer not to say.” To assess self- 
reported sleep duration, participants were asked, “About how many 
hours sleep do you get in every 24 hours? (please include naps),” 
with responses in hour increments. To assess frequent insomnia 
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symptoms, subjects were asked, “Do you have trouble falling asleep 
at night or do you wake up in the middle of the night?” with re-
sponses “never/rarely,” “sometimes,” “usually,” and “prefer not to 
answer.” Subjects who responded “Prefer not to answer” (n = 637) 
were set to missing. Insomnia symptoms were dichotomized into 
controls (“never/rarely”) and cases with frequent insomnia symp-
toms (“usually”), with those reporting “sometimes” excluded. To 
assess daytime napping, subjects were asked, “Do you have a nap 
during the day?” with response options “Never/rarely,” “Sometimes,” 
“Usually,” and “Prefer not to answer.” Self-reported EDS was 
ascertained using the question “How likely are you to dose off or fall 
asleep during the daytime when you don’t mean to? (e.g., when 
working, reading, or driving)” with response options “Never/rarely,” 
“Sometimes,” “Often,” “All of the time,” “Do not know,” and “Prefer 
not to answer.” Subjects reporting “Do not know” and “Prefer not 
to answer” were set to missing. Other responses were coded contin-
uously as 1 to 4 corresponding to the severity of EDS. Subjective 
overall health was reported in response to the question “In general, 
how would you rate your overall health?” Those who self-reported 
“Excellent” or “Good” overall health were classified as “healthy,” 
and those who self-reported “Fair” or “Poor” overall health were 
classified as “unhealthy.”
Genetic association analysis
Genome-wide genotyping was performed by the U.K. Biobank, and 
genotyping, quality control, and imputation procedures have been 
previously described in detail (66). We further clustered subjects 
into four ancestry clusters using K-means clustering on the principal 
components, identifying 453,964 subjects of European ancestry. 
Genetic association analysis was performed, as previously described 
(7), in related subjects of European ancestry using BOLT (67) linear 
mixed models and an additive genetic model adjusted for age, sex, 
10 principal components, genotyping array, and genetic correlation 
matrix with a maximum per-SNP missingness of 10% and per-sample 
missingness of 40%. We tested for an association between SNPs in 
the genomic intervals encompassing ERBB4 and KSR2. Genomic 
intervals were defined using recombination hotspots upstream and 
downstream of the gene of interest and correspond to the National 
Center for Biotechnology Information Build 37/hg19 positions 
211.94 to 213.49 Mb for ERBB4 and 117.81 to 118.47 Mb for KSR2. 
Linear/logistic regression was performed adjusting for age, sex, 
10 principal components of ancestry, and genotyping array. Additional 
adjustment for body mass index was performed in the regression 
model for difficulty waking up and EDS. Association testing for 
daytime napping excluded those with self-reported poor overall 
health (“unhealthy”; n = 60,712). Reported SNPs were significant at 
the stringent genome-wide significant level used in GWAS (P < 5 × 
10−8). Locus zoom plots were generated using LocusZoom using the 
HG19 1000 genomes European genetic panel for genetic linkage 
data (68).
ERBB4 and KSR2 SNP eQTL analysis in  
Genome-Tissue Expression
The Genome-Tissue Expression (GTEx) Project (69) data portal 
(accessed 1 July 2019) was used to investigate genetic effects of the 
genome-wide significant association signals at ERBB4 and KSR2 on 
gene expression across 48 tissues (data source: GTEx data version 
V7; n = 620 individuals). GTEx version V7 eQTL analysis (described 
in the data portal) used gene expression measured using RNA se-
quencing (Illumina TruSeq) with inclusion of samples with an RNA 
integrity number (as measured by Agilent Bioanalyzer) of 6.0 or 
higher, and quality control measures included genes >0.1 transcripts 
per kilobase million in at least 20% of samples and ≥6 reads in at 
least 20% of samples. Expression values were quantile-normalized 
between samples, and for each gene, expression values were normal-
ized across samples using an inverse normal transform. SNPs were 
genotyped in GTEx using whole-genome sequencing from blood 
samples. SNPs with a minor allele frequency ≥1% were used. Asso-
ciation analyses were linear regression analyses that were adjusted 
for sex, genotyping platform, and the top three genotyping-based 
principal components to adjust for potential population stratification 
by race/ethnicity and sample size–dependent complex nongenetic 
PEER (probabilistic estimation of expression residuals) factors (70). 
The normalized effect size of the eQTLs was defined as the slope 
of the linear regression based on the human genome reference 
GRCh37/hg19. The normalized effect sizes were computed in a nor-
malized space where magnitude had no direct biological interpreta-
tion. A false discovery rate < 0.05 was used to correct for multiple 
hypothesis testing.
Statistical analysis
Behavioral data were processed using MATLAB (MathWorks), 
graphs were generated using Excel (Microsoft), and statistical 
analyses were performed using Prism 6 (GraphPad). The number of 
humans, animals, and statistical tests used are stated in each figure 
or figure legend. Line graphs in Figs. 1 to 4 and figs. S1 and S3 to S8 
were generated from raw data and averaged over 1-hour bins in 10-min 
intervals to show underlying behavioral trends. Bar graphs show 
mean ± SEM. Box plots extend from the 25th to the 75th percentile, 
with the median marked by a horizontal line in the box, and whiskers 
extend from the 10th to the 90th percentile of data points. In all 
zebrafish statistical tests, the significance threshold was set to 
P < 0.05, and P values were adjusted for multiple comparisons 
where appropriate. Parametric analyses were applied because the 
data followed an approximately normal distribution in nearly all 
cases. Unpaired two-tailed Student’s t test was performed using Excel. 
One-way and two-way ANOVA and post hoc tests to correct for 
multiple comparisons were performed using Prism. The Holm-Sidak 
post hoc test was used to correct for multiple comparisons and to 
allow pairwise comparison of means for all samples. Asterisks in 
figures denote statistics for pairwise or multiple comparisons as indi-
cated. The GCaMP6s/tdTomato fluorescence data and sleep rebound 
data were not normally distributed, so a Wilcoxon rank-sum non-
parametric test was used to test for significant differences.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/11/eaax4249/DC1
Fig. S1. Effects of gain and loss of EGFR signaling on sleep architecture.
Fig. S2. Amino acid alignment of human and zebrafish TGFa, EGF, and EGFR.
Fig. S3. Gefitinib does not enhance egfra−/− phenotype and effects of EGFR inhibitors on sleep 
architecture.
Fig. S4. EGFR signaling is not required for behavioral circadian rhythms.
Fig. S5. Validation of an SD assay, and EGFR signaling is required for normal homeostatic 
regulation of sleep.
Fig. S6. Inhibition of MAPK/ERK signaling suppresses TGFa overexpression–induced sleep.
Fig. S7. EGFR signaling regulates npvf expression, and TGFa overexpression–induced sleep is 
suppressed in npvf mutant animals.
Fig. S8. Association of ERBB4 sleepiness allele with increased ERBB4 expression in humans and 
pharmacological inhibition of KSR2 or ERBB4 decrease sleep in zebrafish.
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Table S1. Variants at ERBB4 and KSR2 associate with self-reported measures of sleep quality 
and quantity in U.K. Biobank subjects.
Table S2. Descriptive characteristics of U.K. Biobank subjects of European ancestry used for 
sleep trait analysis.
View/request a protocol for this paper from Bio-protocol.
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